Internal Medicine

Amyloidosis

Questions discussed in this category

What are your top takeaways in Hematologic Malignancies from ASH 2024?

12 Answers available

Would testing for ATTR cardiac amyloidosis be considered in an older patient with bilateral carpal tunnel surgeries and multiple spinal stenosis surgeries, but no obvious cardiac symptoms?

1 Answer available

What would be your index of suspicion for AL amyloidosis with cardiac involvement in a patient with MGUS to prompt further imaging (and which modality would be preferred)?

1 Answer available

How do you approach treating a patient with IgM-AL amyloidosis?

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...

3 Answers available

What options are available for patients with relapsed/refractory AL amyloidosis after Dara-CyBorD, other than clinical trial?

1 Answer available

What is your approach to a patient with systemic AL amyloidosis who has achieved a hematologic response but not an organ response with CyBorD?

Would you proceed to autologous transplant, or switch to an alternate regimen (eg. daratumumab-based) first? Would the type or degree of organ involv...

1 Answer available

How do you approach the workup and initial treatment of systemic AL amyloidosis?

Once a tissue biopsy has confirmed light chain amyloid, what additional tests do you perform as part of a standard workup? In whom should treatment b...

1 Answer available

Papers discussed in this category

N Engl J Med,

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993-05

Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.

British journal of haematology, 2018-10

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Blood Adv,

Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.

Blood Cancer J, 2020 May 11

Venetoclax for the treatment of translocation (11;14) AL amyloidosis.

Lancet Oncol, 2020 Oct 29

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.

Blood Cancer J, 2021 Jan 11

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

Blood advances, 2018-05-22

Epidemiology of AL amyloidosis: a real-world study using US claims data.

JACC CardioOncol, 2020 Mar 17

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis.

Mayo Clin Proc, 2010 Aug 16

Prevalence of monoclonal gammopathy of undetermined significance: a systematic review.

ESC Heart Fail, 2021 Dec 08

Echocardiographic and clinical predictors of cardiac amyloidosis: limitations of apical sparing.

Cancer, 2023 Jun 24

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Related Topics in Internal Medicine